Mifegymiso, which Hyundai has applied for permission, will be discussed at the Central Pharmaceutical Advisory Committee, the MFDS' legal advisory body.

The Central Pharmaceutical Advisory Committee's consultation is expected to determine whether Mifegymiso will conduct a bridging study in Korea.

The MFDS will hold a meeting at the Central Pharmaceutical Advisory Committee on the 2nd to ask whether Mifegymiso-related safety and validity are reasonable. The meeting is expected to receive comments on the current controversial Bridging Study.

"We will discuss Mifegymiso's Bridging Study at the Central Pharmaceutical Advisory Committee," said an official at the MFDS. "Based on